AC Immune SA (ACIU)
2.40
+0.01
(+0.42%)
USD |
NASDAQ |
May 06, 16:00
2.23
-0.17
(-7.08%)
Pre-Market: 08:47
AC Immune Cash from Investing (Quarterly): 25.14M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 25.14M |
| September 30, 2023 | 6.088M |
| June 30, 2023 | -4.332M |
| March 31, 2023 | 46.22M |
| December 31, 2022 | 5.446M |
| September 30, 2022 | -5.321M |
| June 30, 2022 | 25.38M |
| March 31, 2022 | -0.5846M |
| December 31, 2021 | -23.92M |
| September 30, 2021 | -0.2653M |
| June 30, 2021 | -33.66M |
| March 31, 2021 | -0.8734M |
| December 31, 2020 | 3.941M |
| September 30, 2020 | 16.51M |
| June 30, 2020 | 9.986M |
| March 31, 2020 | -0.2191M |
| December 31, 2019 | -5.101M |
| September 30, 2019 | -11.51M |
| Date | Value |
|---|---|
| June 30, 2019 | -0.0142M |
| March 31, 2019 | -50.69M |
| December 31, 2018 | -31.01M |
| September 30, 2018 | -0.1431M |
| June 30, 2018 | -0.3707M |
| March 31, 2018 | -1.223M |
| December 31, 2017 | 0.0364M |
| September 30, 2017 | -0.3189M |
| June 30, 2017 | -0.9492M |
| March 31, 2017 | -0.6383M |
| December 31, 2016 | -0.2843M |
| September 30, 2016 | -0.3121M |
| June 30, 2016 | -0.1048M |
| March 31, 2016 | -0.2114M |
| December 31, 2015 | -0.0059M |
| September 30, 2015 | -0.1235M |
| June 30, 2015 | -0.0391M |
| March 31, 2015 | -0.0851M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-33.66M
Minimum
Jun 2021
46.22M
Maximum
Mar 2023
2.784M
Average
-0.2191M
Median
Mar 2020
Cash from Investing (Quarterly) Benchmarks
| CRISPR Therapeutics AG | -81.45M |
| Addex Therapeutics Ltd | -0.0012M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 21.20M |
| MoonLake Immunotherapeutics | 116.87M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.21M |
| Cash from Financing (Quarterly) | 45.65M |
| Free Cash Flow | -68.17M |
| Free Cash Flow Per Share (Quarterly) | -0.2004 |
| Free Cash Flow to Equity (Quarterly) | -17.38M |
| Free Cash Flow to Firm (Quarterly) | -17.38M |
| Free Cash Flow Yield | -33.44% |